All analyses
AI analysis

HNB Life PLC: research report

Moderately undervaluedbearishNov 9, 2026

Evidence points weaker because September profit fell 36% despite revenue growth. The counterweight is a moderately undervalued market-wide score of 74.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • September-quarter net profit fell 35.9% to LKR 178 million while net margin fell to 1.6%, its worst September result in seven comparable filings.
  • Total liabilities were 4.71 times equity at December 2025, up from 3.99 times a year earlier, increasing the importance of investment and insurance-liability management.

Against this. The shares score 74 of 100 on price against book value, earnings and dividends, placing them in the moderately undervalued fifth of the market.

Net margin
1.6%sector 1.4%
from 3.2% a year earlier, revenue +23.9%
Return on equity
17.8%
twelve months to Sep 30, 2026, unaudited
P/E
8.7sector 15.6
earnings Rs 15.73 per share, year to Sep 2026
P/B
1.54sector 1.46
book Rs 88.20 per share
Dividend yield
3.67%sector 1.83%
31.8% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 9, 2026. Sector figures are the median of 11 listed companies in the same sector.

Overview

HNB Life operates life and general insurance businesses in Sri Lanka through agency, bancassurance and alternate distribution channels. The latest quarter combined strong top-line growth with a materially weaker profit result, making the durability of underwriting and investment income the central issue rather than sales momentum alone.

Price performance

At LKR 134 on 6 November 2026, HASU had fallen 4.6% over one month while the ASPI gained 5.0%; over three months it fell 11.5% against a 0.6% ASPI decline. The divergence is consistent with company-specific concerns, although the supplied filings and recent news do not establish a cause.

The share sits 12.1% below its 52-week high and 65.1% up its range from the low. Sixty-day volatility was 29.9% below its own one-year norm, while trading volume was 18.3% above the preceding 60-day level, indicating a quieter price pattern but somewhat more recent activity.

The three-year record contains three falls of 15% or more, the deepest 23%, which took six months to recover. Liquidity is limited: a LKR 1 million order is more than everything that trades on a typical day (128% of it), so even a modest position represents a large part of normal daily turnover.

Valuation

The LKR 134 price values trailing profit at a P/E of 8.5 times, or 8.5 rupees for every rupee of the last twelve months' profit, placing it at the 25th percentile among nine insurance peers with usable P/E data. P/B is 1.52 times, meaning 1.52 rupees for each rupee of net assets, while the latest audited return on equity was 16.9%; that profitability helps explain why the shares trade above book value.

The apparent sector discount conflicts with the company's own record: P/B is more expensive than 90% of days since January 2019, and P/E is more expensive than 84% of days over the same period. A buyer at this price is relying only modestly on the latest quarter, which supplied 7.6% of trailing EPS; had that quarter achieved its year-ago net margin, the same price would equate to 7.9 times earnings rather than 8.5 times.

The 3.7% dividend yield is supported by a LKR 5.00 FY2025 distribution, up from LKR 3.90 in each of FY2024 and FY2023. The FY2025 dividend's ex-date was 31 March 2026, so a buyer today does not receive it.

News and sentiment

Direct coverage was normal but sparse in the latest 90 days, with one material article and a positive sentiment classification. An article reported on 7 August that life gross written premium rose 43% in the first half of 2026, but this predates the September filing and does not resolve the subsequent quarterly profit decline.

There was no company news in the last 30 days. Board and senior-management appointments at the general-insurance subsidiary were reported in July and May, respectively, but neither carried quantified earnings terms.

Financials

September-quarter revenue rose 23.9% year-on-year to LKR 10.9 billion, yet net profit fell 35.9% to LKR 178 million. Revenue growth therefore did not translate into profit growth for the shares being valued. Net margin fell from 3.1% to 1.6%, meaning the group retained about 2 cents less from each revenue rupee than a year earlier; it was the worst September net margin in seven comparable filings.

Gross and operating margins are unavailable for both the September 2026 and September 2025 quarters, so no like-for-like comparison can be made for those measures. The latest audited full year, ended December 2025, recorded a 10.1% operating margin and a 7.1% net margin, but that annual result predates the weaker September quarter and should not be treated as current trading.

Equity rose to LKR 13.2 billion from LKR 12.9 billion a year earlier, while the share count remained 150 million. There is therefore no corporate-action-driven change in the per-share comparison. The September filing does not provide operating profit or a below-the-line bridge, leaving the source of the profit decline unresolved.

Risks

The foremost risk is that the September profit contraction follows rising revenue: a 1.6% net margin was the weakest September outcome in seven comparable observations, so the current earnings base is thin relative to the premium and revenue volume being written.

As an insurer, liabilities are central to the funding model. Total liabilities were 4.71 times equity at the December 2025 audited year-end, versus 3.99 times a year earlier, meaning LKR 4.71 of obligations supported each rupee of equity. Changes in bond yields can affect fixed-income portfolio valuations and reinvestment yields, while recent rupee movement is relevant to foreign-currency reinsurance and claims costs; these are sector conditions, not company-specific outcomes.

Outlook

As at 9 November 2026, the next scheduled evidence is the audited year to 31 December 2026, expected between 28 April and 3 June 2027. It will show whether the September profit weakness was confined to one quarter or persisted through the year, and will update the insurer's liability and equity position.

No further dated corporate action is listed. The available data cannot separate the September profit decline between underwriting, investment income, finance costs, tax or other items because the operating-profit line and below-the-line bridge are unavailable for that filing.

About this report. Generated on Nov 9, 2026 from market data up to Nov 6, 2026, 1 material news articles over 90 days and financials to Sep 30, 2026, and scored 74 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports